{"url":"https://lda.senate.gov/api/v1/filings/cbb32fbe-2ebd-40c1-8d8f-d7bee0eb96fd/","filing_uuid":"cbb32fbe-2ebd-40c1-8d8f-d7bee0eb96fd","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/cbb32fbe-2ebd-40c1-8d8f-d7bee0eb96fd/print/","filing_document_content_type":"text/html","income":null,"expenses":"670000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Elizabeth Grammer","dt_posted":"2025-01-17T13:51:32-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"34175 Ardenwood Boulevard","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Fremont","registrant_state":"CA","registrant_zip":"94555","registrant":{"id":401105832,"url":"https://lda.senate.gov/api/v1/registrants/401105832/","house_registrant_id":null,"name":"ARDELYX, INC.","description":"Biopharmaceutical company","address_1":"34175 Ardenwood Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Freemont","state":"CA","state_display":"California","zip":"94555","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ELIZABETH GRAMMER","contact_telephone":"+1 510-745-1705","dt_updated":"2026-07-30T15:45:39.643015-04:00"},"client":{"id":207922,"url":"https://lda.senate.gov/api/v1/clients/207922/","client_id":12,"name":"ARDELYX, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142055,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"PEREIRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147593,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LASH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147594,"prefix":null,"prefix_display":null,"first_name":"KENNETH","nickname":null,"middle_name":null,"last_name":"SPRAGUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147595,"prefix":null,"prefix_display":null,"first_name":"REBECCA","nickname":null,"middle_name":null,"last_name":"WALDROP","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148292,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"KRIBS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147594,"prefix":null,"prefix_display":null,"first_name":"KENNETH","nickname":null,"middle_name":null,"last_name":"SPRAGUE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}